HSRx Group In-Licenses Portfolio of Novel Late-Stage Orphan and Breakthrough Combination Drugs, Acquires Ready-for-Market OTC Drugs

Aug 05, 2015, 13:55 ET from HSRx Group

TUCSON, Ariz., Aug. 5, 2015 /PRNewswire/ -- Addressing today's pressing public health challenges, HSRx Group, an Arizona-based biopharmaceutical company, is developing a new generation of combination drugs that dramatically improve treatment and prevention therapies for complex disease conditions.

These targeted therapies are being developed at a time when cardiovascular, neurodegenerative and metabolic lifestyle diseases are approaching epidemic stages, and viral and bacterial infectious disease conditions are demonstrating resistance to current drug treatments. "A new generation of treatment therapies to effectively engage the multiple human body mechanisms involved in these complex diseases is desperately needed," notes HSRx Executive Chairman Robert Gow.

HSRx is addressing these critical health issues by pairing proprietary food-based compounds with FDA-approved generic drugs. HSRx creates novel, patentable combination drugs that, in late-stage FDA-regulated human clinical studies, demonstrate superior treatment results and improved safety profiles. These products target Orphan and Breakthrough Drug disease categories that qualify for FDA fast track market approval.

"Our combination drugs engage multiple disease-related human body mechanisms, not just a single mechanism as do the current generation of drugs. Engaging multiple mechanisms is proven to be more effective in treating complex diseases," Gow says. "This advancement is strongly attractive to companies desiring fast access to market share in blockbuster drug categories."

The HSRx proprietary OTC product portfolio is fully developed and immediately marketable, offering valuable line extensions in each of the top-selling OTC health condition categories. All HSRx drugs – for acne, allergies, cold and flu, sleep disorders, athlete's foot, joint pain and more – meet FDA requirements and qualify for Natural or Organic label claims. Each is verified in independently-conducted human clinical trials to outperform the category's current market leader product. 

HSRx will license or joint-venture its products with select pharmaceutical, OTC drug or direct-to-consumer marketing companies. "We are presently sequencing 19 products through comparative studies and marketing launch," said HSRx Managing Director Thomas Sullivan, Jr.

HSRx acquired a portfolio of ten proprietary OTC drug products and in-licensed 8 proprietary disease-specific pharmaceutical products from HerbalScience Group, LLC ("HSG"), a leading Florida-based biosciences company. HSG's global network of medical and engineering researchers perfected technologies to identify foods' bioactive phytochemicals and the human body mechanisms that these substances influence to beneficially effect disease-related gene expression.

About HSRx Group

HSRx Group is a biopharmaceutical company developing a new generation of combination drugs for the prevention and treatment of a broad group of chronic diseases, including influenza, Alzheimer's, rheumatoid arthritis, solid tumor cancer, MRSA, type 1 diabetes, vascular dementia and stroke.  Its technology integrates the disease-fighting chemistry of foods with select generic drugs to create unique pharmaceutical products with long patent lives. HSRx products equip healthcare providers with payer- and patient-friendly multiple-mechanism disease mitigation therapy options. More information is available at HSRxGroup.com


Matt Russell

Russell Public Communications

(520) 232-9840